Betta Pharmaceuticals Co., Ltd. (SHE:300558)
China flag China · Delayed Price · Currency is CNY
50.48
-0.07 (-0.14%)
Aug 31, 2026, 3:04 PM CST

Betta Pharmaceuticals Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Cash & Equivalents
455.19429.98471.68752731.28791.99
Trading Asset Securities
0.5766126.440.54-201.01
Cash & Short-Term Investments
455.75495.98598.12752.54731.28993
Cash Growth
-21.08%-17.08%-20.52%2.91%-26.36%-35.35%
Accounts Receivable
624.88351.2698.47286.41450.62173.38
Other Receivables
18.7377.951.832.6149.740.75
Receivables
643.61429.21100.3289.02500.32214.13
Inventory
363.35381.16290.09327.5372.17293.32
Prepaid Expenses
---0.2--
Other Current Assets
278.83271.48235.82156.62129.06153.49
Total Current Assets
1,7421,5781,2241,5261,7331,654
Property, Plant & Equipment
2,8872,9623,0092,5742,0561,331
Long-Term Investments
2,2562,5831,4371,382919.27345.79
Goodwill
383.65413.58413.58413.58413.58413.58
Other Intangible Assets
2,6332,6042,7761,9441,2191,183
Long-Term Accounts Receivable
13.6813.289.29---
Long-Term Deferred Tax Assets
58.9259.1356.7339.1385.9655.06
Long-Term Deferred Charges
234220.16383.531,2191,4441,252
Other Long-Term Assets
91.0613332.750.339.337.6
Total Assets
10,29910,5669,3429,1477,9106,271

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Accounts Payable
457.22512.32746.11800.1235.85431.19
Accrued Expenses
350.22390.16285.53357.82419.11357.02
Short-Term Debt
2.55100.08300.27380.39-
Current Portion of Long-Term Debt
1,132824.19639.85301.25--
Current Portion of Leases
47.5446.6533.034.64.164.88
Current Income Taxes Payable
25.7547.244.260.070.0410.68
Current Unearned Revenue
2.682.372.634.924.460.69
Other Current Liabilities
37.7789.3636.4734.111,26184.4
Total Current Liabilities
2,0551,9171,8481,8032,105888.86
Long-Term Debt
1,2501,5241,5521,816656.03-
Long-Term Leases
39.7362.8471.638.187.36.34
Long-Term Unearned Revenue
180.23226.22150.99144.7112.76112
Long-Term Deferred Tax Liabilities
100.26167.9153.4923.3971.5768.39
Other Long-Term Liabilities
37.74----510.06
Total Liabilities
3,6633,8983,6763,7952,9521,586

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Common Stock
420.73420.73418.49418.49417.47415.39
Additional Paid-In Capital
2,2322,1642,0762,1421,8601,932
Retained Earnings
3,2953,0562,8342,5032,1812,139
Comprehensive Income & Other
678.83954.47245.21188.3390.9974.64
Total Common Equity
6,6266,5955,5745,2514,8494,561
Minority Interest
10.872.5392.3100.4108.64124.9
Shareholders' Equity
6,6376,6685,6665,3514,9584,686
Total Liabilities & Equity
10,29910,5669,3429,1477,9106,271

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Total Debt
2,4712,4622,3962,4301,04811.22
Net Cash (Debt)
-2,015-1,966-1,798-1,678-316.59981.77
Net Cash Growth
------35.97%
Net Cash Per Share
-4.81-4.70-4.29-4.00-0.762.36
Filing Date Shares Outstanding
420.73420.73418.49418.49417.47415.39
Total Common Shares Outstanding
420.73420.73418.49418.49417.47415.39
Working Capital
-313.66-339.45-623.63-277.28-371.95765.08
Book Value Per Share
15.7515.6813.3212.5511.6210.98
Tangible Book Value
3,6093,5772,3842,8943,2162,964
Tangible Book Value Per Share
8.588.505.706.927.707.14
Buildings
3,0443,0412,952586.14585.59627.19
Machinery
459.6461.18449.64424.26402.25376.01
Construction In Progress
235.38227.31191.872,0371,448639.67